Wir sind mit live! Mehr erfahren
XBIT-Symbol

XBiotech
XBIT

2,12 USD
-0,04
1,85 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
1 Tag
-1,85 %
5 Tage
-7,42 %
1 Monat
-1,4 %
3 Monate
-7,42 %
6 Monate
-12,76 %
Seit Jahresbeginn
-10,92 %
1 Jahr
-14,86 %
5 Jahre
-83,68 %
10 Jahre
-84,77 %
 

Profil: XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Mitarbeiter: 87

Gesundheitswesen Biotechnologie

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 0 %
Neutral 0 %
Negativ 0 %
Neutral
GlobeNewsWire
vor 4 Monaten
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
Neutral
Accesswire
letztes Jahr
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
Neutral
Accesswire
letztes Jahr
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
letztes Jahr
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
Neutral
Accesswire
letztes Jahr
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
letztes Jahr
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
Neutral
Accesswire
letztes Jahr
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
letztes Jahr
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
Neutral
Accesswire
letztes Jahr
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
letztes Jahr
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
Nachrichtenrankings ansehen
Kursdiagramme mit Lightweight Charts™ umgesetzt